May 24 2012
APP Pharmaceuticals, LLC, a Fresenius Kabi Company, today announced it
has acquired three products from Nexus Pharmaceuticals, Inc. Under terms
of the agreement APP takes complete ownership of the products and
becomes the Abbreviated New Drug Application (ANDA) holder for
Benztropine Mesylate Injection, Levetiracetam Injection and Tranexamic
Acid Injection.
"The addition of these products broadens an already extensive portfolio
of injectable APP critical care products," said John Ducker, president
and chief executive officer of APP Pharmaceuticals. "As leaders in the
reliable supply of sterile generic injectable drugs, APP will continue
to identify, develop and market products to meet customer needs."
Benztropine Mesylate Injection, USP (1mg/mL, 2 mL) is therapeutically
equivalent to the reference-listed drug Cogentin®.
Levetiracetam Injection (100 mg/ml, 5 mL) is therapeutically equivalent
to the reference-listed drug Keppra®. Tranexamic Acid
Injection (100 mg/mL, 10 mL) is therapeutically equivalent to the
reference-listed drug Cyklokapron®. According to IMS Health,
in 2011 these three products combined represented a total market value
of more than $90 million in the United States.
Menopause symptoms disrupt daily life, but few women get treatment